Pro-moieties of antimicrobial peptide prodrugs

Molecules

Volumn 20, Issue 1, 2015, Pages 1210-1227

  Forde, Eanna ^a   Devocelle, Marc ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b University College Dublin   (Ireland)

Author keywords

Antibody; Antimicrobial; Charge; PEG; Peptides; Prodrug

Indexed keywords

ANTIINFECTIVE AGENT; PEPTIDE; PRODRUG;

ANTI-INFECTIVE AGENTS; PEPTIDES; PRODRUGS;

EID: 84921691389     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20011210     Document Type: Review

References (65)

1. Hancock, R.E.; Sahl, H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006, 24, 1551-1557.
2. Hancock, R.E. Cationic peptides: Effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 2001, 1, 156-164.
3. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389-395.
4. Brogden, K.A.; de Lucca, A.J.; Bland, J.; Elliott, S. Isolation of an ovine pulmonary surfactant-associated anionic peptide bactericidal for Pasteurella haemolytica. Proc. Natl. Acad. Sci. USA 1996, 93, 412-416.
5. Vizioli, J.; Salzet, M. Antimicrobial peptides from animals: Focus on invertebrates. Trends Pharmacol. Sci. 2002, 23, 494-496.
6. Sadler, K.; Eom, K.D.; Yang, J.L.; Dimitrova, Y.; Tam, J.P. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 2002, 41, 14150-14157.
7. Westerhoff, H.V.; Juretić, D.; Hendler, R.W.; Zasloff, M. Magainins and the disruption of membrane-linked free-energy transduction. Proc. Natl. Acad. Sci. USA 1989, 86, 6597-6601.
8. Yeaman, M.R.; Bayer, A.S.; Koo, S.P.; Foss, W.; Sullam, P.M. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J. Clin. Investig. 1998, 101, 178-187.
9. Park, S.C.; Park, Y.; Hahm, K.S. The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int. J. Mol. Sci. 2011, 12, 5971-5992.
10. Fjell, C.D.; Hiss, J.A.; Hancock, R.E.; Schneider, G. Designing antimicrobial peptides: Form follows function. Nat. Rev. Drug Discov. 2012, 11, 37-51.
11. Stromstedt, A.A.; Ringstad, L.; Schmidtchen, A.; Malmsten, M. Interaction between amphiphilic peptides and phospholipid membranes. Curr. Opin. Colloid Interface Sci. 2010, 15, 467-478.
12. Schmidtchen, A.; Pasupuleti, M.; Morgelin, M.; Davoudi, M.; Alenfall, J.; Chalupka, A.; Malmsten, M. Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. J. Biol. Chem. 2009, 284, 17584-17594.
13. Devocelle, M. Targeted antimicrobial peptides. Front. Immunol. 2012, 3, 309.
14. Mammalian Host Defence Peptides; Hancock, R., Devine, D., Eds.; Cambridge University Press: New York, NY, USA, 2004; pp. 39-68.
15. Peschel, A.; Sahl, H.G. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 2006, 4, 529-536.
16. Finlay, B.B.; Hancock, R.E. Can innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol. 2004, 2, 497-504.
17. Vandamme, D.; Landuyt, B.; Luyten, W.; Schoofs, L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol. 2012, 280, 22-35.
18. Afacan, N.J.; Yeung, A.T.; Pena, O.M.; Hancock, R.E. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr. Pharm. Des. 2012, 18, 807-819.
19. Yount, N.Y.; Yeaman, M.R. Emerging themes and therapeutic prospects for anti-infective peptides. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 337-360.
20. Taggart, C.C.; Greene, C.M.; Smith, S.G.; Levine, R.L.; McCray, P.B., Jr.; O'Neill, S.; McElvaney, N.G. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J. Immunol. 2003, 171, 931-937.
21. Bergsson, G.; Reeves, E.P.; McNally, P.; Chotirmall, S.H.; Greene, C.M.; Greally, P.; Murphy, P.; O'Neill, S.J.; McElvaney, N.G. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J. Immunol. 2009, 183, 543-551.
22. Fitzgerald-Hughes, D.; Devocelle, M.; Humphreys, H. Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: Two novel alternatives. FEMS Immunol. Med. Microbiol. 2012, 65, 399-412.
23. Giuliani, A.; Rinaldi, A.C. Beyond natural antimicrobial peptides: Multimeric peptides and other peptidomimetic approaches. Cell. Mol. Life Sci. 2011, 68, 2255-2266.
24. Giuliani, A.; Pirri, G.; Nicoletto, S. Antimicrobial peptides: An overview of a promising class of therapeutics. Cent. Eur. J. Biol. 2007, 2, 1-33.
25. Zhang, L.; Scott, M.G.; Yan, H.; Mayer, L.D.; Hancock, R.E. Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers. Biochemistry 2000, 39, 14504-14514.
26. Steinstraesser, L.; Kraneburg, U.M.; Hirsch, T.; Kesting, M.; Steinau, H.U.; Jacobsen, F.; Al-Benna, S. Host defense peptides as effector molecules of the innate immune response: A sledgehammer for drug resistance? Int. J. Mol. Sci. 2009, 10, 3951-3970.
27. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: Design and clinical applications. Nat. Rev. Drug Discov. 2008, 7, 255-270.
28. Sorensen, O.E.; Follin, P.; Johnsen, A.H.; Calafat, J.; Tjabringa, G.S.; Hiemstra, P.S.; Borregaard, N. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001, 97, 3951-3959.
29. Goldberg, K.; Sarig, H.; Zaknoon, F.; Epand, R.F.; Epand, R.M.; Mor, A. Sensitization of Gram-negative bacteria by targeting the membrane potential. FASEB J. 2013, 27, 3818-3826.
30. Falagas, M.E.; Kasiakou, S.K. Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 2005, 40, 1333-1341.
31. Velkov, T.; Roberts, K.D.; Nation, R.L.; Thompson, P.E.; Li, J. Pharmacology of polymyxins: New insights into an 'old' class of antibiotics. Future Microbiol. 2013, 8, 711-724.
32. Maiz, L.; Giron, R.M.; Olveira, C.; Quintana, E.; Lamas, A.; Pastor, D.; Canton, R.; Mensa, J. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: Systematic review of randomised controlled trials. Expert Opin. Pharmacother. 2013, doi:10.1517/14656566.2013.790366.
33. Greally, P.; Whitaker, P.; Peckham, D. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr. Med. Res. Opin. 2012, 28, 1059-1067.
34. Bergen, P.J.; Li, J.; Rayner, C.R.; Nation, R.L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2006, 50, 1953-1958.
35. Young, D.C.; Zobell, J.T.; Waters, C.D.; Ampofo, K.; Stockmann, C.; Sherwin, C.M.; Spigarelli, M.G. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: Iv. Colistimethate sodium. Pediatr. Pulmonol. 2013, 48, 1-7.
36. Li, J.; Turnidge, J.; Milne, R.; Nation, R.L.; Coulthard, K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 2001, 45, 781-785.
37. Jiang, T.; Olson, E.S.; Nguyen, Q.T.; Roy, M.; Jennings, P.A.; Tsien, R.Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. USA 2004, 101, 17867-17872.
38. Desgranges, S.; le Prieult, F.; Daly, A.; Lydon, J.; Brennan, M.; Rai, D.K.; Subasinghage, A.P.; Hewage, C.M.; Cryan, S.A.; Greene, C.; et al. In vitro activities of synthetic host defense propeptides processed by neutrophil elastase against cystic fibrosis pathogens. Antimicrob. Agents Chemother. 2011, 55, 2487-2489.
39. Forde, E.; Humphreys, H.; Greene, C.M.; Fitzgerald-Hughes, D.; Devocelle, M. Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis. Antimicrob. Agents Chemother. 2014, 58, 978-985.
40. Jang, J.H.; Kim, M.Y.; Lee, J.W.; Kim, S.C.; Cho, J.H. Enhancement of the cancer targeting specificity of buforin IIb by fusion with an anionic peptide via a matrix metalloproteinases-cleavable linker. Peptides 2011, 32, 895-899.
41. Warren, P.; Li, L.; Song, W.; Holle, E.; Wei, Y.; Wagner, T.; Yu, X. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus. Cancer Res. 2001, 61, 6783-6787.
42. Holle, L.; Song, W.; Holle, E.; Nilsson, J.; Wei, Y.; Li, J.; Wagner, T.E.; Yu, X. In vivo targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus. Mol. Med. Rep. 2009, 2, 399-403.
43. Banerjee, S.S.; Aher, N.; Patil, R.; Khandare, J. Poly(ethylene glycol)-prodrug conjugates: Concept, design, and applications. J. Drug Deliv. 2012, 2012, doi:10.1155/2012/103973.
44. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6, 688-701.
45. Harris, J.M.; Chess, R.B. Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2, 214-221.
46. Tomlinson, R.; Heller, J.; Brocchini, S.; Duncan, R. Polyacetal-doxorubicin conjugates designed for pH-dependent degradation. Bioconjugate Chem. 2003, 14, 1096-1106.
47. Veronese, F.M.; Schiavon, O.; Pasut, G.; Mendichi, R.; Andersson, L.; Tsirk, A.; Ford, J.; Wu, G.; Kneller, S.; Davies, J.; et al. PEG-doxorubicin conjugates: Influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjugate Chem. 2005, 16, 775-784.
48. Duncan, R.; Kopeckova-Rejmanova, P.; Strohalm, J.; Hume, I.; Cable, H.C.; Pohl, J.; Lloyd, J.B.; Kopecek, J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer 1987, 55, 165-174.
49. Ulbrich, K.; Etrych, T.; Chytil, P.; Jelinkova, M.; Rihova, B. Hpma copolymers with pH-controlled release of doxorubicin: In vitro cytotoxicity and in vivo antitumor activity. J. Control. Release 2003, 87, 33-47.
50. Imura, Y.; Nishida, M.; Ogawa, Y.; Takakura, Y.; Matsuzaki, K. Action mechanism of tachyplesin I and effects of PEGylation. Biochim. Biophys. Acta 2007, 1768, 1160-1169.
51. Imura, Y.; Nishida, M.; Matsuzaki, K. Action mechanism of PEGylated magainin 2 analogue peptide. Biochim. Biophys. Acta 2007, 1768, 2578-2585.
52. Singh, S.; Papareddy, P.; Morgelin, M.; Schmidtchen, A.; Malmsten, M. Effects of PEGylation on membrane and lipopolysaccharide interactions of host defense peptides. Biomacromolecules 2014, 15, 1337-1345.
53. Morris, C.J.; Beck, K.; Fox, M.A.; Ulaeto, D.; Clark, G.C.; Gumbleton, M. PEGylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery. Antimicrob. Agents Chemother. 2012, 56, 3298-3308.
54. Zhang, G.; Han, B.; Lin, X.; Wu, X.; Yan, H. Modification of antimicrobial peptide with low molar mass poly(ethylene glycol). J. Biochem. 2008, 144, 781-788.
55. Nollmann, F.I.; Goldbach, T.; Berthold, N.; Hoffmann, R. Controlled systemic release of therapeutic peptides from PEGylated prodrugs by serum proteases. Angew. Chem. Int. Ed. Engl. 2013, 52, 7597-7599.
56. Forde, E. Host Defense Peptide Prodrugs for Use in Cystic Fibrosis. Ph.D. Thesis, Royal College of Surgeons in Ireland, Dublin, Ireland, 2015.
57. Franzman, M.R.; Burnell, K.K.; Dehkordi-Vakil, F.H.; Guthmiller, J.M.; Dawson, D.V.; Brogden, K.A. Targeted antimicrobial activity of a specific IgG-SMAP28 conjugate against Porphyromonas gingivalis in a mixed culture. Int. J. Antimicrob. Agents 2009, 33, 14-20.
58. Szynol, A.; de Haard, J.J.; Veerman, E.C.; de Soet, J.J.; van Nieuw Amerongen, A.V. Design of a peptibody consisting of the antimicrobial peptide dhvar5 and a llama variable heavy-chain antibody fragment. Chem. Biol. Drug Des. 2006, 67, 425-431.
59. Eckert, R.; He, J.; Yarbrough, D.K.; Qi, F.; Anderson, M.H.; Shi, W. Targeted killing of Streptococcus mutans by a pheromone-guided "smart" antimicrobial peptide. Antimicrob. Agents Chemother. 2006, 50, 3651-3657.
60. Qiu, X.Q.; Wang, H.; Lu, X.F.; Zhang, J.; Li, S.F.; Cheng, G.; Wan, L.; Yang, L.; Zuo, J.Y.; Zhou, Y.Q.; et al. An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria. Nat. Biotechnol. 2003, 21, 1480-1485.
61. Qiu, X.Q.; Zhang, J.; Wang, H.; Wu, G.Y. A novel engineered peptide, a narrow-spectrum antibiotic, is effective against vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 2005, 49, 1184-1189.
62. He, J.; Anderson, M.H.; Shi, W.; Eckert, R. Design and activity of a "dual-targeted" antimicrobial peptide. Int. J. Antimicrob. Agents 2009, 33, 532-537.
63. Arnusch, C.J.; Pieters, R.J.; Breukink, E. Enhanced membrane pore formation through high-affinity targeted antimicrobial peptides. PLoS One 2012, 7, e39768.
64. Desgranges, S.; Ruddle, C.C.; Burke, L.P.; McFadden, T.M.; O'Brien, J.E.; Fitzgerald-Hughes, D.; Humphreys, H.; Smyth, T.P.; Devocelle, M. Beta-lactam-host defence peptide conjugates as antibiotic prodrug candidates targeting resistant bacteria. RSC Adv. 2012, 2, 2480-2492.
65. Kennedy, D.A.; Vembu, N.; Fronczek, F.R.; Devocelle, M. Synthesis of mutual azo prodrugs of anti-inflammatory agents and peptides facilitated by alpha-aminoisobutyric acid. J. Org. Chem. 2011, 76, 9641-9647.